ARA-290 (Cibinetida): what it is and what the evidence says
A peptide studied for its relationship with tissue-repair pathways and modulation of discomfort associated with neural inflammation.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Tissue repair happens in phases, not all at once: an initial inflammation that is actually useful, the building of new tissue, and then its remodelling, which can take months. Compounds studied in this area relate to one of those phases. None of them replaces rest or rehabilitation, and that is precisely the most common mistake people make when reading about them.
What it is studied for
Recovery, comfort, inflammatory balance.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
It is among the peptides in this encyclopedia with the best clinical backing: there are randomized controlled phase 2 trials in small-fiber neuropathy associated with sarcoidosis, in type 2 diabetes and in diabetic macular edema, with objective measures such as corneal nerve fiber density.
The limitation that matters most
Despite those trials it remains an investigational drug with no regulatory approval in any indication: the samples are small, the follow-ups short, and a good share of the studies come from the same group and from the sponsor developing the molecule.
Regulatory status
Not approved for any indication. In clinical investigation (phase 2).
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Developing research; variable individual response.
With neurological or metabolic conditions, prioritize professional assessment.
What this page cannot give you
A reference page can take you this far. You know what ARA-290 (Cibinetida) is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a diploma with a verifiable folio, a record to track how you progress, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber densityhuman Mol Med · 2013 · PMID 24136731 →
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabeteshuman Mol Med · 2015 · PMID 25387363 →
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Painhuman Invest Ophthalmol Vis Sci · 2017 · PMID 28475703 →
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edemahuman J Clin Med · 2020 · PMID 32674280 →
- Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug actionhuman Eur Neuropsychopharmacol · 2015 · PMID 26431906 →
- Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathyhuman Sci Rep · 2018 · PMID 29549285 →
- ARA 290 for treatment of small fiber neuropathy in sarcoidosisreview Expert Opin Investig Drugs · 2014 · PMID 24555851 →
- ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia responsepreclinical Mol Pain · 2014 · PMID 24529189 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for ARA-290 (Cibinetida) or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is ARA-290 (Cibinetida)?
A peptide studied for its relationship with tissue-repair pathways and modulation of discomfort associated with neural inflammation. It is studied within the area of regenerative.
Is there human evidence for ARA-290 (Cibinetida)?
It is among the peptides in this encyclopedia with the best clinical backing: there are randomized controlled phase 2 trials in small-fiber neuropathy associated with sarcoidosis, in type 2 diabetes and in diabetic macular edema, with objective measures such as corneal nerve fiber density.
Is it approved by any health agency?
Not approved for any indication. In clinical investigation (phase 2).
What is the dose of ARA-290 (Cibinetida)?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what ARA-290 (Cibinetida) is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.